KNSAHIGH SIGNALFINANCIAL10-K

KNSA achieved a dramatic turnaround from significant losses to strong profitability with operating income swinging from -$45.6M to +$77.2M while revenue grew 60%.

This represents a fundamental transformation of the business model, moving from cash-burning to cash-generating operations with operating cash flow surging 437% to $138M. The company appears to have reached an inflection point where its commercialization efforts are translating into sustainable profitability and strong cash generation.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

KNSA delivered exceptional financial performance with revenue growing 60% to $677.6M while achieving a remarkable turnaround from -$45.6M operating loss to +$77.2M operating profit, supported by operating cash flow that surged 437% to $138M. The balance sheet strengthened significantly with current assets growing 59% to $527.2M, though inventory doubled to $54.9M and accounts receivable declined 63%, suggesting improved collections but potential demand buildup. Overall, the financials signal a company that has successfully transitioned from development-stage losses to profitable commercial operations with strong cash generation capabilities.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+466.1%
$277K→$1.6M

Capital expenditure jumped 466.1% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+437.1%
$25.7M→$138.0M

Operating cash flow surged 437.1% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+269.3%
-$45.6M→$77.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+236.6%
-$43.2M→$59.0M

Net income grew 236.6% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
+108.2%
$26.4M→$54.9M

Inventory surged 108.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Accounts Receivable
Balance Sheet
-62.6%
$41.7M→$15.6M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Revenue
P&L
+60.1%
$423.2M→$677.6M

Strong top-line growth of 60.1% — accelerating demand or successful expansion into new markets.

Current Assets
Balance Sheet
+58.9%
$331.8M→$527.2M

Current assets grew 58.9% — improving short-term liquidity or inventory/receivables build.

Current Liabilities
Balance Sheet
+38.3%
$100.6M→$139.2M

Current liabilities surged 38.3% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+37.9%
$142.1M→$196.0M

Liabilities grew 37.9% — significant increase in debt or obligations, assess impact on financial flexibility.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
Employer Identification Number) Kiniksa Pharmaceuticals International, plc 105 Piccadilly, Second Floor London , W1J 7NJ England , United Kingdom ( 781 ) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp.
In December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.
KPL-387 is an independently developed asset that we believe may expand the recurrent pericarditis market and provide an additional treatment option for patients, with the potential to add the convenience of monthly subcutaneous self-administration with a liquid formulation.
In July 2025, we announced that the Phase 2 dose-focusing portion of the Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis had begun recruiting.
We expect data from the Phase 2 portion of the trial in the second half of 2026 and plan to use the totality of the data to determine further development strategy.
+7 more — sign up free →
REMOVED
Employer Identification Number) Kiniksa Pharmaceuticals International, plc 23 Old Bond Street, Floor 3 London , W1S 4PZ England , United Kingdom ( 781 ) 431-9100 (Address, zip code and telephone number, including area code of principal executive offices) Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue Lexington, MA, 02421 (781) 431-9100 (Address, zip code and telephone number, including area code of agent for service) Kiniksa Pharmaceuticals, Ltd.
Food and Drug Administration (the FDA ) or regulatory authorities in other jurisdictions; potential and ongoing coverage and reimbursement for our products and product candidates, if approved; clinical and commercial activities; research and development costs; timing of regulatory filings and feedback; timing and likelihood of success; and plans and objectives of management for future operations and funding requirements, are forward-looking statements.
Industry and other data Unless otherwise indicated, certain industry data and market data included in this Annual Report were obtained from independent third party surveys, market research, publicly available information, reports of governmental agencies and industry publications and surveys.
KPL-387 is an independently developed asset that we believe has the potential to further advance recurrent pericarditis treatment options for patients by providing the added convenience of monthly subcutaneous dosing with a liquid formulation.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →